AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00557011 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule taken once daily in the morning
Study NCT00875108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIAject™
Description: Subcutaneous injection 25 IU/mL
Study NCT03183089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rohto Dry-Aid®
Study NCT03764449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Balovaptan
Description: In Period 1, IV infusion of balovaptan was administered after the balovaptan oral dose.~In Period 2, IV infusion of balovaptan was administered after the final oral dose of balovaptan.
Study NCT00169000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine at the following dose levels for 14 days every 21 days, beginning with dose level 1~Dose level -2 600 mg/m2 po BID~Dose level -1 700 mg/m2 po BID~Dose level 1 825 mg/m2 po BID~Dose level 2 1000 mg/m2 po BID
Study NCT00169000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2 over one hour on day 8 of each cycle
Study NCT00379522 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasopressin
Description: 10 minutes after standard shock treatment 10 IU arginine vasopressin will be injected; if shock persists for 5 minutes, another 10 IU arginine vasopressin will be injected; after 5 minutes persisting shock, the last 10 IU arginine vasopressin will be injected; Total duration: approx. 15 minutes; Dose per intravenous injection: 10 IU; max. dose: 30 IU arginine vasopressin
Study NCT00379522 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: Placebo for arginine vasopressin
Study NCT03362359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga-68-PSMA-11
Description: Single administration of 150 MBq (± 50 MBq), corresponding to a mass dose of ≤ 6 µg. A 2nd administration of 150 MBq (± 50 MBq), corresponding to a mass dose of ≤ 6 µg is possible in the unlikely case of a negative histological result (i.e. no prostate-specific membrane antigen (PSMA) expression in dissected lymph nodes) to verify if PSMA PET-positive tissue as seen on day 1 has not been removed during RP with EPLND.
Study NCT01370525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Nexium 20 mg administered as 22.3 mg of esomeprasole magnesium hydrate, capsule, oral dose
Study NCT01370525 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Esomeprazole
Description: Nexium 20 mg administered as 22.3 mg of esomeprasole magnesium hydrate, capsule, oral dose
Study NCT03376867 — intervention group
Intervention type: OTHER
Intervention: Conditioned pain modulation
Description: Conditioned pain modulation (CPM) protocol consist of evaluating pain during two stimuli test (heat and pressure point), before and after one conditioning stimulus (cold water bath); Blood analyses for biochemistry and genes polymorphisms.
Study NCT01705496 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [124I]FIAU
Description: This is a single dose study of 5 mCi \[124I\]FIAU in subjects presenting with pain in a prosthetic knee or hip joint. Subject will receive two PET-CT scans after \[124I\]FIAU injection.
Study NCT03159520 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Advice sheet
Description: Advice on management of post orthodontic pain
Study NCT00498979 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa-2b
Description: recombinant interferon alfa-2b
Study NCT00498979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: recombinant interferon alfa-2b
Study NCT00498979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium stibogluconate
Description: sodium stibogluconate
Study NCT00498979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacarbazine
Description: dacarbazine
Study NCT00498979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinblastine
Description: vinblastine
Study NCT00415610 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: nicardipine
Description: Intravenous (IV) nicardipine infusion. It is expected that the treatment duration will vary between 18 and 24 hours.~* Started at 5mg/h~* Titrated by 2.5mg/hour every 15 minutes to bring systolic blood pressure in target range for the applicable Tier. Max dose 15mg/hour \*Once target systolic blood pressure reached, dose decreased by 2.5mg/hour every 15 minutes until systolic blood pressure maintained in the target range or the medication is discontinued.
Study NCT03087344 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fibroscan and Acoustic Radiation Force Impulse
Description: Liver stiffness and spleen stiffness will be measured before and after a standard meal is administered by Fibroscan and Acoustic Radiation Force Impulse
Study NCT02491788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Study NCT02491788 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02444559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 20ml 5mg/ml+ Clonidine 150ug
Study NCT02444559 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine 20ml 5mg/ml+ Placebo
Study NCT00679783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2281
Description: PARP inhibitor Olaparib tablets, oral
Study NCT03087344 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fibroscan
Description: Liver stiffness will be measured before and after a standard meal is administered
Study NCT03087344 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acoustic Radiation Force Impulse
Description: Liver stiffness and spleen stiffness will be measured before and after a standard meal is administered by Fibroscan and Acoustic Radiation Force Impulse
Study NCT04030858 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Plant-based diet + nutrition education
Description: The intervention group will adopt a nutrient-dense dietary pattern and receive nutrition education sessions specific to that lifestyle. The diet protocol is comprised of minimally-processed plant foods such as fruits, vegetables, legumes, beans, nuts and seeds. No refined sugars, added salt, or oil will be included. Dietary fat intake limited to 20% of total calories or less per day. Animal products will be eliminated. This dietary pattern is expected to improve resilience, mood, inflammation, microbiome, spirituality, and overall general health (as measured by weight, cholesterol, blood pressure). The treatment group will also receive weekly nutrition education sessions to support the diet.
Study NCT04028349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV/MVA-BN-Filo
Description: Candidate Ebola Vaccine
Study NCT00964834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline and Valortim
Description: Days 1-5 100mg IV Doxycycline BID over 60 minutes. Day 6 20mg/kg Valortim IV over 60 minutes.
Study NCT00964834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Antibiotic and Valortim
Description: Days 1-5 20mg/kg IV Normal Saline BID over 60 minutes. Day 6 20mg/kg IV Valortim over 60 minutes.
Study NCT03183089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systane® Ultra
Study NCT03813836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Patients will receive best supportive care + pembrolizumab 200mg every 3 weeks for a maximum duration of 24 months
Study NCT00964834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Antibiotic and Placebo Valortim
Description: Days 1-5 200mL IV Normal Saline for Placebo Antibiotic BID over 60 minutes. Day 6 20mg/kg IV Normal Saline for Placebo Valortim over 60 minutes.
Study NCT03239860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNbAC1 Monoclonal Antibody
Description: Monthly IV
Study NCT03067454 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Early mobilisation
Description: Conservative treatment with early mobilisation~The patient is instructed to do a fist and is not allowed to leave the clinic before. Active mobilisation under control (doctor or physiotherapist) is performed until healing of the fracture is documented.
Study NCT03067454 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Operation
Description: Operation of the fracture. Usually open reduction and internal fixation with plates and screws or just screws within 2 weeks of injury. Immobilisation in a cast for two weeks followed by physiotherapy.
Study NCT00877084 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Resistance training: series of 3x8 repetitions will be performed for the quadriceps muscle at 70% of the 1 Repetition Maximum determined as the weight the patient can lift once over the full range of motion. The weight can be applied using free weights or using a classical multi-gym device or a quadriceps chair.
Study NCT00877084 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: usual care according to clinical pathway for COPD, No training
Study NCT01479998 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Description: standard care plus nicotine replacement therapy
Study NCT01479998 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard care plus contingency management
Description: standard care is 4 counseling sessions and nicotine replacement therapy plus 3 weekly meetings with positive reinforcers
Study NCT02300857 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low carbohydrate diet
Description: Feeding study. Composition (by proportion of calories): 20% carbohydrate, 60% fat, 20% protein
Study NCT02300857 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate carbohydrate diet
Description: Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein
Study NCT02300857 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High carbohydrate diet
Description: Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein
Study NCT02449382 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: continuous venovenous hemofiltration
Description: If the serum sodium concentration >150mmol/L, When filter occurred clotting, replace the filter to CVVH treatment
Study NCT02449382 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: If the serum sodium concentration ≤150mmol/L, When filter occurred clotting, as the end of treatment.
Study NCT03612648 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Three Fraction Accelerated Partial Breast Irradiation
Description: * TRI-APBI simulation must take place no more than 8 weeks from final definitive breast surgery~* Machines that could be used include: SAVI applicator, The ViewRay System for Radiation Therapy, The ViewRay (MRIdian) Linac System, Halcyon, True Beam, True Beam STx, Edge Radiotherapy Delivery System
Study NCT03612648 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial mastectomy
Description: -Standard of Care
Study NCT01267292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone
Description: \[week 1: Buspirone 30 mg twice a day (9am and 6pm) on Monday through Sunday\] \[weeks 2-3: Buspirone 45 mg twice a day (9am and 6pm) on Monday through Sunday\]
Study NCT01267292 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Buspirone
Description: \[week 1: Placebo for Buspirone twice a day (9am and 6pm) on Monday through Sunday\] \[weeks 2-3: Placebo for Buspirone twice a day (9am and 6pm) on Monday through Sunday\]
Study NCT01267292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Methylphenidate serves as an acute stimulant challenge. \[week 1: no Methylphenidate or Methylphenidate placebo\] \[week 2: 0mg Methylphenidate (placebo for Methylphenidate) on Monday at 10am; Methylphenidate once a day (10am) on Wednesday and Friday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)\] \[week 3: Methylphenidate once a day (10am) on Monday and Wednesday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)\]
Study NCT01267292 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylphenidate
Description: Methylphenidate serves as an acute stimulant challenge. \[week 1: no Methylphenidate or Methylphenidate placebo\] \[week 2: 0mg Methylphenidate (placebo for Methylphenidate) on Monday at 10am; Methylphenidate once a day (10am) on Wednesday and Friday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)\] \[week 3: Methylphenidate once a day (10am) on Monday and Wednesday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)\]
Study NCT01267292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Methylphenidate
Description: \[week 1: no Methylphenidate or Methylphenidate placebo\] \[week 2: 0mg Methylphenidate (placebo for Methylphenidate) on Monday at 10am; Methylphenidate once a day (10am) on Wednesday and Friday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)\] \[week 3: Methylphenidate once a day (10am) on Monday and Wednesday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)\]
Study NCT01267292 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Methylphenidate
Description: \[week 1: no Methylphenidate or Methylphenidate placebo\] \[week 2: 0mg Methylphenidate (placebo for Methylphenidate) on Monday at 10am; Methylphenidate once a day (10am) on Wednesday and Friday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)\] \[week 3: Methylphenidate once a day (10am) on Monday and Wednesday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)\]
Study NCT03238898 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A
Description: botulinum toxin type A injections~Botulinum toxin type A (100 or 30 units) was injected for each side into the gastrocnemious or the small flexor foot muscles, respectively, according to the predominance of leg or foot cramps.
Study NCT03238898 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline injections~The same dosage as the active group, but with normal saline alone were injected into the gastrocnemious or the small flexor foot muscles, respectively, according to the predominance of leg or foot cramps.
Study NCT04074421 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin
Description: A non-aminoglycoside intestinal antibiotic, 400mg, twice one day for 2 weeks.
Study NCT04074421 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Probiotic Formula
Description: A probiotic called Enterococcus faecium, 500mg, triple one day for 4 weeks.
Study NCT04074421 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo oral tablet that has no therapeutic effect
Study NCT00766233 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyperthermal treatment
Description: Hyperthermal treatment one or three times per week for 60 minutes
Study NCT02459262 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GBS-NN vaccine
Description: Three dose levels will be administered, with and without Alhydrogel®
Study NCT02459262 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: GBS-NN vaccine
Description: Three dose levels will be administered, with and without Alhydrogel®
Study NCT03925701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: vildagliptin twice daily
Study NCT03925701 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vildagliptin\metformin
Description: vildagliptin\\metformin twice daily
Study NCT01904864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: elemental iron (NovaFerrum®)
Description: single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation, NovaFerrum®, for 12 weeks
Study NCT01904864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: elemental iron (Ferrous Sulfate)
Description: single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation, Ferrous Sulfate, for 12 weeks
Study NCT01737957 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-fluence PRP with 532nm green LASER
Description: To administer low-fluence PRP in a single session for PDR
Study NCT01737957 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Full-Fluence PRP with 532nm LASER
Description: To administer full-fluence PRP in two sessions for PDR
Study NCT00111748 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Velcade, Thalidomide, Dexamethasone
Description: Dosage and Administration Schedule Each cycle will consist of 3 weeks (21 days). AGENT DOSE ROUTE DAYS Velcade 1.0 mg/m2 IV 1, 4, 8, and 11 Thalidomide 100 mg PO Daily, hs Dexamethasone 20 mg PO Days 1, 2, 4,5, 8, 9, 11, 12 Lovenox 40 mg SQ Days 1-14~This 21-day period will be considered one treatment cycle; Cycle 2 would commence on Day 22 (Cycle 2, Day 1). The next cycle of treatment may be delayed up to day 29 due to non-toxicity reasons. Patients may continue to receive treatment every 21 days, provided there is no evidence of disease progression or no unacceptable toxicity for a maximum of eight cycles. At the discretion of the treating physician, patients may be eligible to receive treatment at their local physician after completion of the 1st cycle. These patients will need to return to MIRT prior to every cycle for cycles 2-4, cycles 6 and 8, and final visit.
Study NCT02187913 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resistant starch
Description: Each subject will complete 2 testing days (randomized and crossover design). On each of 2 test days, subjects will arrive at the Purdue Clinical Research Center after a 12-h fast and will consume a snack bar containing resistant starch. The test snack bar will be consumed along with a standard meal provided at the start of the test day. A second standard meal that does not contain the snack bar will be consumed four hours later.
Study NCT01953497 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: URC102
Study NCT01953497 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00772785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probuphine (buprenorphine implant)
Description: Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug. (4 implants 6-month duration)
Study NCT00331344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride
Description: Given IV
Study NCT01968733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solithromycin
Study NCT01968733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Study NCT00331344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Description: Given IV
Study NCT00331344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given orally
Study NCT00121654 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal cord stimulation
Description: Under sterile conditions and local anesthesia, the epidural space is punctured at the level of T5-T6 and a quadripolar electrode catheter is introduced and advanced under X-ray control into the epidural space. A suitable position for the electrode catheter is sought for, corresponding to the site where a prickling sensation (paresthesia) is felt and covers the area of radiation of angina pain under neurostimulation. The electrode catheter is connected to an internal pulse generator placed in a subcutaneous abdominal or gluteal pocket through an extension lead connected to the electrode by subcutaneous tunneling.
Study NCT01490502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Patients will be assigned to low dose (600 IU/day) versus high-dose (5000 IU/day) of vitamin D3 as an add-on therapy to glatiramer acetate (Copaxone).
Study NCT01774747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSP-1053
Description: DSP-1053 10, 15, 20, 30, 45, 60, 90 mg once daily for 14 days
Study NCT01774747 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DSP-1053
Description: DSP-1053 10, 15, 20, 30, 45, 60, 90 mg once daily for 14 days
Study NCT01774747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo 10, 15, 20, 30, 45, 60, 90 mg once daily for 14 days
Study NCT01774747 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 10, 15, 20, 30, 45, 60, 90 mg once daily for 14 days
Study NCT03168295 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dapagliflozin 10mg then Placebo Oral Tablet
Description: SGLT2 inhibitor - Dapagliflozin then Placebo
Study NCT03168295 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg then Placebo Oral Tablet
Description: SGLT2 inhibitor - Dapagliflozin then Placebo
Study NCT03168295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg then Placebo Oral Tablet
Description: SGLT2 inhibitor - Dapagliflozin then Placebo